| Indicators | Browse All

Citius Oncology, Inc. (CTOR)

Healthcare | Drug Manufacturers - Specialty & Generic | Cranford, United States | NasdaqCM
0.77 USD +0.02 (3.204%) ⇧ (Oct. 16, 2026, 10:25 a.m. EDT)

Short-term:★⯪☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 4:48 a.m. EDT

The immediate outlook is severely clouded by a relentless downward price trend over the last two years, which has erased roughly 84% of the company's value despite a recent single-year recovery. While the latest year-on-year performance shows a rebound, the market has clearly priced in significant structural risks, evidenced by a massive 3.4 beta and a price-to-book ratio of 2.2 times despite negative equity generation. The balance sheet is fragile, with operating cash flow burning at nearly $20 million annually and a current ratio below 0.75, forcing the company to rely on capital raises rather than organic liquidity. Although there is a glimmer of commercial progress with international orders for LYMPHIR and near-100% payer coverage, the financial reality remains precarious. With no dividend to provide income and a high short interest suggesting skepticism among leveraged players, the security offers no margin of safety for investors at these levels.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.108572
AutoETS0.110621
AutoARIMA0.111145
AutoTheta0.117196

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 32%
H-stat 1.19
Ljung-Box p 0.000
Jarque-Bera p 0.154
Excess Kurtosis -1.25
Attribute Value
Sector Healthcare
Debt to Equity Ratio 25.282
Revenue per Share 0.076
Market Cap 81,423,848
Beta 3.40
Website https://citiusonc.com/overview/default.aspx

Info Dump

Attribute Value
52 Week Change -0.5611765
Address1 11 Commerce Drive
Address2 First Floor
All Time High 49.0
All Time Low 0.491
Ask 1.8
Ask Size 1
Average Daily Volume10 Day 83,980
Average Daily Volume3 Month 102,898
Average Volume 102,898
Average Volume10Days 83,980
Beta 3.4
Bid 0.707
Bid Size 2
Book Value 0.382
City Cranford
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.7699
Current Ratio 0.726
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 0.7699
Day Low 0.7699
Debt To Equity 25.282
Display Name Citius Oncology
Dividend Yield 0.0
Ebitda Margins 0.0
Enterprise To Revenue 10.21
Enterprise Value 72,542,768
Eps Trailing Twelve Months -0.48
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.86644
Fifty Day Average Change -0.096539974
Fifty Day Average Change Percent -0.11142142
Fifty Two Week Change Percent -56.11765
Fifty Two Week High 1.95
Fifty Two Week High Change -1.1801
Fifty Two Week High Change Percent -0.6051794
Fifty Two Week Low 0.491
Fifty Two Week Low Change 0.27890003
Fifty Two Week Low Change Percent 0.5680245
Fifty Two Week Range 0.491 - 1.95
Financial Currency USD
First Trade Date Milliseconds 1,670,509,800,000
Float Shares 30,982,094
Free Cashflow -31,167,442
Full Exchange Name NasdaqCM
Fullday Change 0.023900032
Fullday Change Percent 3.2037578
Fullday Price 0.7699
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.74815005
Gross Profits 5,315,776
Has Pre Post Market Data 1
Held Percent Insiders 0.77511
Held Percent Institutions 0.15213001
Implied Shares Outstanding 105,758,982
Industry Drug Manufacturers - Specialty & Generic
Industry Disp Drug Manufacturers - Specialty & Generic
Industry Key drug-manufacturers-specialty-generic
Language en-US
Last Fiscal Year End 1,759,190,400
Long Business Summary Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Long Name Citius Oncology, Inc.
Market us_market
Market Cap 81,423,848
Market State REGULAR
Max Age 86,400
Message Board Id finmb_1859892474
Most Recent Quarter 1,782,777,600
Net Income To Common -46,064,264
Next Fiscal Year End 1,790,726,400
Non Diluted Market Cap 106,816,571
Number Of Analyst Opinions 1
Open 0.7699
Operating Cashflow -19,389,240
Operating Margins -5.95554
Phone 908 967 6677
Previous Close 0.746
Price Hint 4
Price To Book 2.015445
Price To Sales Trailing12 Months 11.45976
Profit Margins 0.0
Quick Ratio 0.293
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.023900032
Regular Market Change Percent 3.2037578
Regular Market Day High 0.7699
Regular Market Day Low 0.7699
Regular Market Day Range 0.7699 - 0.7699
Regular Market Open 0.7699
Regular Market Previous Close 0.746
Regular Market Price 0.7699
Regular Market Time 1,792,160,717
Regular Market Volume 924
Return On Assets -0.29118
Return On Equity -1.2658
Revenue Per Share 0.076
Sand P52 Week Change 0.16207206
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 105,758,982
Shares Percent Shares Out 0.0027
Shares Short 289,717
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 468,965
Short Name Citius Oncology, Inc.
Short Percent Of Float 0.0098
Short Ratio 2.86
Source Interval 15
State NJ
Symbol CTOR
Target High Price 4.0
Target Low Price 4.0
Target Mean Price 4.0
Target Median Price 4.0
Total Cash 16,563,705
Total Cash Per Share 0.157
Total Debt 10,210,272
Total Revenue 7,105,197
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.48
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 0.86059
Two Hundred Day Average Change -0.09068996
Two Hundred Day Average Change Percent -0.105381146
Type Disp Equity
Volume 924
Website https://citiusonc.com/overview/default.aspx
Zip 7,016